Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2055550 | 0.87 | IDH1 (0.43) | BRD4POLBNOTUMGAA | |
| SCHEMBL8114506 | 0.80 | NOTUM (0.43) | BRD4HDAC9POLBL3MBTL1NOTUM | |
| SCHEMBL1786936 | 0.80 | HDAC9 (0.44) | BRD4HDAC9POLBL3MBTL1NOTUM | |
| SCHEMBL9526787 | 0.78 | BRD4 (0.41) | BRD4HDAC9POLBL3MBTL1NOTUM | |
| Hydrochloric Acid SCHEMBL9526798 | 0.78 | HDAC9 (0.43) | BRD4HDAC9POLBL3MBTL1NOTUM | |
| SCHEMBL30047054 | 0.77 | NOTUM (0.38) | NOTUMALDH1A1MEN1KMT2A | |
| SCHEMBL14173250 | 0.76 | ALDH1A1 (0.47) | POLBALDH1A1MEN1KMT2A | |
| SCHEMBL13620657 | 0.76 | HDAC9 (0.40) | HDAC9POLBL3MBTL1NOTUMALDH1A1 | |
| SCHEMBL1470334 | 0.75 | MEN1 (0.47) | BRD4HDAC9POLBL3MBTL1NOTUM | |
| SCHEMBL855461 | 0.74 | BRD4 (0.41) | BRD4HDAC9POLBL3MBTL1NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2023-01-12 | — | — | US | disclosed |
| US-20200087266-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2020-03-19 | — | — | US | disclosed |
| EP-3456713-A1 | PROCESS FOR THE PREPARATION OF TRIAZINE DERIVATIVES | Japan Tobacco Inc. (JP) | 2019-03-20 | — | — | EP | disclosed |
| EP-3109240-B1 | TRIAZINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | JAPAN TOBACCO INC (JP) | 2018-10-24 | — | — | EP | disclosed |
| EP-3109240-A1 | TRIAZINE COMPOUND AND USE THEREOF FOR MEDICAL PURPOSES | Japan Tobacco, Inc. (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2015-09-24 | — | — | US | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| US-8921380-B2 | Pyrazolo[1,5-a] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2014-12-30 | — | — | US | disclosed |
| EP-2520577-A1 | Pyrazolo[1,5-a]pyrimidine compounds as CB1 receptor antagonists | Mitsubishi Tanabe Pharma Corporation (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | TANIMOTO KOICHI (JP) | 2012-08-09 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-8163759-B2 | Pyrazolo[1,5-A] pyrimidine compounds as CB1 receptor antagonist | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-04-24 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-10-15 | — | — | US | disclosed |
| WO-2008004698-A2 | PYRAZOLO [1, 5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202992-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | BRD4 39/4885HDAC9 1344/4885POLB 3296/4885 |
| US-20150266834-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | BRD4 4305/4885HDAC9 1403/4885POLB 3003/4885 |
| US-20090258867-A1 | PYRAZOLO[1,5-A] PYRIMIDINE COMPOUNDS AS CB1 RECEPTOR ANTAGONIST | CNR1, CNR2, CCKAR | BRD4 51/4885HDAC9 1312/4885POLB 3550/4885 |
| US-20200087266-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | BRD4 4305/4885HDAC9 1403/4885POLB 3003/4885 |
| US-20230011968-A1 | TRIAZINE COMPOUNDS AND PHARMACEUTICAL USE THEREOF | PTGIS, PTGS1, PTGES | BRD4 4305/4885HDAC9 1403/4885POLB 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.